PYY

CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity

Retrieved on: 
Tuesday, March 26, 2024
Research, FDA, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Human, PYY, Obesity, Neuropeptide, Appetite, Patient, Weight loss, Trial of the century, IND, Nausea, PYY3-36, Safety, Pharmacokinetics, Therapy, Vomiting, Y2R, Pharma, Food, DSM-IV codes, Pharmaceutical industry

With the commencement of the trial, CinFina also announced the first cohort of participants has been dosed.

Key Points: 
  • With the commencement of the trial, CinFina also announced the first cohort of participants has been dosed.
  • The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of CIN-110 in a randomized, double-blind, placebo-controlled, single ascending dose study in otherwise healthy subjects with obesity.
  • PYY3-36 is an endogenous hormone secreted in the gut, which activates the neuropeptide Y2 receptor (Y2R) to reduce appetite and food intake.
  • “The preclinical program of CIN-110 underscores the potential for PYY to be a differentiated approach to treat obesity.

Your body already has a built-in weight loss system that works like Wegovy, Ozempic and Mounjaro – food and your gut microbiome

Retrieved on: 
Wednesday, January 17, 2024
Diabetes, Obesity, Flavonoid, Taste, Nutrient, Patient, Gastroparesis, Weight gain, Health, GIP, Depression, Addiction, Digestion, Food, Weight loss, Nausea, Sleep, Extrapyramidal system, Diet, Hormone, University, Pancreatitis, PYY, Constipation, Gastrointestinal tract, Movement, Disease, Splenic infarction, DSM-IV codes, Medicine, Carotenoid, Population, Diarrhea, Inflammation, Stroke, Stomach, Plant, Exercise, Overweight, Blood, Brain, Metabolism, Appetite, Vomiting, Cardiovascular disease, Pancreas, Polyphenol, Pharmaceutical industry

Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news.

Key Points: 
  • Wegovy, Ozempic and Mounjaro are weight loss and diabetes drugs that have made quite a splash in health news.
  • They target regulatory pathways involved in both obesity and diabetes and are widely considered breakthroughs for weight loss and blood sugar control.
  • Here’s an inside-out perspective on the role natural gut hormones and healthy food play in metabolism and weight loss.

A broken gut

  • These include GLP-1, a natural version of Wegovy and Ozempic.
  • GLP-1 and other hormones like PYY help regulate blood sugar through the pancreas.
  • Prior to modern processed foods, metabolic regulatory pathways were under the direction of a diverse healthy gut microbiome that used these hormones to naturally regulate your metabolism and appetite.
  • Removal of these key food components and the resulting decrease in gut microbiome diversity may be an important factor contributing to the rise in obesity and diabetes.

A short track to metabolic health

  • Researchers have demonstrated their effectiveness at weight loss and blood sugar control.
  • These drugs complement other measures like gastric bypass surgery that are used in the most extreme cases of metabolic disease.
  • Medical guidelines support the use of new incretin-based medications like Wegovy, Ozempic and Mounjaro to manage the interrelated metabolic conditions of diabetes, obesity and cardiovascular disease.

A near-magic bullet – for the right folks


Despite the success and prospect of these drugs to help populations that may benefit most from them, current prescribing practices have raised some questions. Should people who are only a little overweight use these drugs? What are the risks of prescribing these drugs to children and adolescents for lifelong weight management?

  • These symptoms are related to how the drugs work to slow the gastrointestinal tract.
  • Other more severe, but rare, side effects include pancreatitis and irreversible gastroparesis, or inflammation of the pancreas and stomach paralysis.

All roads lead to lifestyle

  • Despite our greatest aspirations for quick fixes, it’s very possible that a healthy lifestyle remains the most important way to manage metabolic disease and overall health.
  • This includes regular exercise, stress management, sleep, getting outdoors and a balanced diet.


Christopher Damman is on the scientific advisory board at One BIO and Supergut.

CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Pharmaceutical, Health, CNS, DPP, Peptide, Patient, MOVE, Investigational New Drug, Human, Diabetes, Bangladesh Technical Education Board, Pharma, Inflammation, Energy, Diet, Safety, Treatment, IND, Cardiovascular disease, Division, Wellness, Harvard Medical School, Brigham, PYY, Overweight, Society, Physician, Obesity medicine, Adipose tissue, Medicine, FACP, DSM-IV codes, SAB, Pharmacokinetics, Defense, Peptide YY, Identification, Weill Cornell Medicine, Research, Nutritional science, The New York Times, Metabolism, DASH, NIH, Weight loss, Pharmaceutical industry, Soft drink, Dietary supplement, Obesity

CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, today announced the scientific advisory board (SAB) members for the company’s multi-asset pipeline.

Key Points: 
  • CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, today announced the scientific advisory board (SAB) members for the company’s multi-asset pipeline.
  • The members of CinFina’s SAB include renowned metabolic and obesity academic researchers and expert clinicians.
  • Louis Aronne, M.D., FACP is a professor of metabolic research at Weill-Cornell Medical College, and director of the Center for Weight Management and Metabolic Clinical Research.
  • His research activities focus on understanding the mechanisms responsible for metabolic abnormalities associated with obesity and the therapeutic effects of weight loss.

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes

Retrieved on: 
Wednesday, November 8, 2023
INAF, Meal, Research, Trial of the century, Faculty, Fasting, Stomach, Peptide YY, Endocrine gland, Membrane protein, GIP, Human, Regulatory News Service, Université Laval, Hyperinsulinemia, Agonal respiration, PYY, Type 2 diabetes, Inflammation, Fibrinogen, Metabolism, Volunteering, Development, Glycated hemoglobin, Phase, Prediabetes, Food court, Lipid, Disease, Risk, Plant, Medicine, Research and development, Faculty of Medicine, King Mongkut's Institute of Technology Ladkrabang, Medical school, Industrial Affairs Committee (Iceland), Partnership, Sensation, Blood, Nutrition, Hormone, CET, Safety, Insulin resistance, Overweight, Gastric inhibitory polypeptide, Glucose, Insulin, Pharmaceutical industry, Dietary supplement, Medical device, Animal feed

Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes

Key Points: 
  • Valbiotis announces the success of the TOTUM•63 mode of action clinical study, against prediabetes and the early stages of type 2 diabetes
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • The study confirms TOTUM•63's efficacy results, in particular the lasting reduction in glycated hemoglobin, one of the main markers of prediabetes and type 2 diabetes.
  • It demonstrates TOTUM•63's multi-target mode of action in subjects at risk, improving the efficacy of energy metabolism, particularly after meals.
  • Mode of action clinical results: TOTUM•63 regulates energy metabolism
    In addition to the positive clinical efficacy studies already conducted, the mode of action study was carried out on 19 overweight or obese volunteers at risk of developing type 2 diabetes.

Kallyope Enters Phase 2 With First-in-class Oral Approach for the Treatment of Both Obesity and Type 2 Diabetes

Retrieved on: 
Wednesday, September 27, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Obesity, Type 2 diabetes, Therapy, Public, Cardiovascular disease, Weight loss, PYY, Research and development, Development, Type 2, CCK, Patient, Physician, Bariatric surgery, Research, GI, Safety, Pharmaceutical industry

The trial, K-757 P006 , aims to demonstrate the weight-loss efficacy, safety, and tolerability of these novel agents for patients with obesity, a growing epidemic in the United States.

Key Points: 
  • The trial, K-757 P006 , aims to demonstrate the weight-loss efficacy, safety, and tolerability of these novel agents for patients with obesity, a growing epidemic in the United States.
  • Weight loss can play an important role in helping patients living with obesity to manage serious health consequences including Type 2 diabetes, cardiovascular disease, and high cholesterol.
  • It has been well demonstrated that oral treatments are highly preferred both by patients and physicians.
  • They are the only known oral nutrient receptor agonists being studied for the treatment of obesity.

Carmot Therapeutics Announces Two Oral Presentations Featuring Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 59th European Association for the Study of Diabetes (EASD) Annual Meeting

Retrieved on: 
Tuesday, September 26, 2023
Volunteering, Obesity, Human body weight, MOA, Therapy, T1D, Weight loss, Clinical trial, Type 2 diabetes, Pharmacokinetics, PYY, DSM-IV codes, Patient, CEST, Overweight, GIP, European Association for the Study of Diabetes, T2D, Diabetes, Medical imaging, Birth control, Communications satellite, Vaccine, Philosopher's stone

BERKELEY, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to delivering life-changing therapeutics for people with metabolic diseases, today announced two oral presentations to take place at the European Association for the Study of Diabetes Annual Meeting from October 2-6, 2023 in Hamburg, Germany. Details regarding the clinical data presentations are as follows:

Key Points: 
  • Carmot expects to initiate additional Phase 2 trials for obesity and T2D.
  • Carmot has recently initiated an additional Phase 1 MOA study in adults with overweight/obesity with type 1 diabetes (T1D) and expects to initiate a Phase 2 proof-of-concept clinical trial in participants with overweight/obesity with T1D.
  • CT-996 (once-daily oral, small molecule GLP-1 receptor agonist) is currently in a multi-arm, multi-cohort Phase 1 clinical trial in adults with overweight/obesity as well as in patients with T2D.
  • A long-acting peptide tyrosine-tyrosine (PYY) analogue, which is in preclinical development.

i2o Therapeutics Names Kurt Graves Chairman and CEO, Announces Corporate Updates

Retrieved on: 
Monday, August 28, 2023
Health, Diabetes, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Executive, Obesity, Prevalence, Harvard University, The Conference Board, Intarcia Therapeutics, Disability, EVP, Policy, Intarsia, PYY, Ionic liquid, IP, Glucagon, Medication, Novartis, Acquisition, Omeprazole, Vertex Pharmaceuticals, ITCA, Merck, Commercial, Therapy, Lancet, Death, House of Medici, Society, GI, Peptide, Disease, Corporate development, Pharmaceutical industry

i2o Therapeutics, Inc. today announced the appointment of Kurt Graves as Chairman, President and CEO.

Key Points: 
  • i2o Therapeutics, Inc. today announced the appointment of Kurt Graves as Chairman, President and CEO.
  • Mr. Graves succeeds i2o co-founder and CEO Ravi Srinivasan, Ph.D., who is pursuing other leadership opportunities within the life sciences field.
  • He has previously served as Chairman, President and CEO of Intarcia Therapeutics, former Chairman of Radius Health, former Executive Chairman of i2o Therapeutics, and as a Board member at Achillion Pharmaceuticals until it was acquired, and at Seres Health.
  • Previously, Mr. Graves served as EVP, Head of Corporate Development, Strategic Drug Development and Program Management and Head of Commercial at Vertex Pharmaceuticals.

Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer

Retrieved on: 
Tuesday, June 6, 2023
Volunteering, Human resources, Business development, IPO, Obesity, MOA, Benjamin Arsanis, Bryant University, Diabetes, T1D, Facility, Clinical trial, Business, Babson College, PYY, Grey, Sale, Acquisition, DSM-IV codes, Patient, CBO, Overweight, CFO, Therapy, T2D, Pharmaceutical industry, Management, Vaccine, Philosopher's stone

BERKELEY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).

Key Points: 
  • BERKELEY, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).
  • In addition, Gray will lead cross-functional teams that include Business Development, Human Resources, IT and Facilities.
  • Gray joins Carmot with nearly 20 years of public-private leadership experience including broad strategic, financial and operating experience in global companies.
  • I am honored to be joining Carmot, a company that is committed to transforming patients' lives through potentially differentiated therapies for metabolic diseases," stated Gray.

Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity

Retrieved on: 
Wednesday, May 31, 2023
Health, Diabetes, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Exercise, Royal Adelaide Hospital, Parameter, Insulin, Obesity, Adelaide, University, Diet, MBBS, Endocrine system, Type 2 diabetes, Glucose, Novel, Duodenum, PYY, Appetite, Doctor of Philosophy, Phase 1, MD, Patient, Physician, American Diabetes Association, Metformin, Bariatric surgery, Therapy, T2D, Treatment, Safety, Disease, Human, Pharmaceutical industry, Medical device, Dietary supplement, Medicine

T2D and obesity are worldwide endemics with millions of people in need of more effective ways to manage their disease.

Key Points: 
  • T2D and obesity are worldwide endemics with millions of people in need of more effective ways to manage their disease.
  • “Type 2 diabetes and obesity are extremely common chronic diseases where the outcome of most therapeutic options is suboptimal.
  • “These Phase 2a data provide clinical evidence that duodenal exclusion may be possible with a non-invasive, orally administered, pharmaceutical treatment.
  • He will discuss therapeutic targets in the gut for the treatment of T2D and obesity.

Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes

Retrieved on: 
Thursday, May 25, 2023
Janus, Volunteering, Obesity, RA, MOA, Diabetes, T1D, Clinical trial, Millennium Management, LLC, PYY, Doctor of Philosophy, Patient, DSM-IV codes, Overweight, Column, Therapy, T2D, Disease, Vaccine, Medical imaging, Pharmaceutical industry, Philosopher's stone

BERKELEY, Calif., May 25, 2023 (GLOBE NEWSWIRE) -- Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced a $150 million oversubscribed and up-sized Series E financing. The financing was led by Deep Track Capital. The syndicate also included new investors 5AM Ventures, Franklin Templeton, Frazier Life Sciences, Janus Henderson Investors, Millennium Management, TCGX, Venrock Healthcare Capital Partners and existing investors RA Capital Management, The Column Group and Willett Advisors. The proceeds from the financing will be used to strengthen Carmot's broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.

Key Points: 
  • The proceeds from the financing will be used to strengthen Carmot's broad portfolio of clinical and preclinical assets designed to modulate gut hormones that are central to energy homeostasis.
  • “With three clinical-stage candidates currently in development, this financing enables us to continue to advance clinical trials that will yield key data readouts this year and through 2024."
  • Results from the multiple ascending dose cohorts will be presented at the 83rd American Diabetes Association Scientific Sessions.
  • By making subtle improvements in molecular design, Carmot may be able to achieve clinically relevant tolerability and efficacy benefits.